Half of the patients who are prescribed statins by their doctor to lower their cholesterol levels reduce the dose or take their treatment irregularly because they believe that these drugs cause muscle pain and other side effects. However, a new study by the European Society of Cardiology, involving more than 4 million patients, shows that the true prevalence of intolerance to statins in the world is between 6 and 10%.
Beware of the nocebo effect
A team of researchers, led by Pr Maciej Banach, from the University of Lodz (Poland), carried out a meta-analysis of 176 studies worldwide in order to identify the global prevalence of intolerance to statins. They were also looking to determine if there were any risk factors for possible intolerance to these cholesterol medications. They found that the overall prevalence was 9.1%. “These results were not a surprise to me, but they were to many other experts. They show that in most cases statin intolerance is overestimated and overdiagnosed, and they mean that approximately 93% of patients on statins can be treated effectively, with very good tolerance and without any safety problems” emphasizes the doctor.
The latter suggests that the perception that patients have of statins, the so-called nocebo effect, (…)
4th dose of anti-Covid vaccine: “probably in October”, for whom?
If you come across this worm in a garden, do not touch it
Covid-19: can we (really) play sports following an injection or an infection?
COVID FIGURES. The results in France this Thursday, February 17 live: announcements, figures
Alzheimer’s: this simple clue in the retina that all ophthalmologists can see
